[{"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.", "fullTimeEmployees": 179, "companyOfficers": [{"maxAge": 1, "name": "Dr. Herve  Brailly Ph.D.", "age": 62, "title": "Co-Founder, Interim CEO & Chairman of Executive Board", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yannis  Morel Ph.D.", "age": 50, "title": "Executive VP, COO & Member of Executive Board", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 402284, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fran\u00e7ois  Romagn\u00e9 Ph.D.", "age": 59, "title": "Founder", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Vivier D.V.M., M.B.A., Ph.D.", "age": 59, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Bonneville Ph.D.", "age": 63, "title": "Founder", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean Jacques Fourni\u00e9 Ph.D.", "title": "Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alessandro  Moretta M.D., Ph.D.", "title": "Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederic  Lombard M.B.A.", "age": 48, "title": "Senior VP & CFO", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sonia  Quaratino M.D., Ph.D.", "age": 56, "title": "Executive VP, Chief Medical Officer & Member of Executive Board", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Arvind  Sood", "title": "Executive VP, President of US Operations & Member of Executive Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 1, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.27, "open": 2.31, "dayLow": 2.31, "dayHigh": 2.31, "regularMarketPreviousClose": 2.27, "regularMarketOpen": 2.31, "regularMarketDayLow": 2.31, "regularMarketDayHigh": 2.31, "beta": 0.789, "forwardPE": 5.133333, "volume": 485, "regularMarketVolume": 485, "averageVolume": 7130, "averageVolume10days": 6030, "averageDailyVolume10Day": 6030, "marketCap": 193957984, "fiftyTwoWeekLow": 1.81, "fiftyTwoWeekHigh": 3.15, "priceToSalesTrailing12Months": 3.1465743, "fiftyDayAverage": 2.17536, "twoHundredDayAverage": 2.47331, "currency": "USD", "enterpriseValue": 127746056, "profitMargins": -0.12281, "floatShares": 31524168, "sharesOutstanding": 80950800, "sharesShort": 66826, "sharesShortPriorMonth": 72858, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0008, "heldPercentInstitutions": 0.00426, "shortRatio": 14.56, "shortPercentOfFloat": 0.0015, "bookValue": 0.642, "priceToBook": 3.5981307, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -7570000, "trailingEps": -0.1, "forwardEps": 0.45, "enterpriseToRevenue": 2.072, "enterpriseToEbitda": -16.857, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "IPHA", "underlyingSymbol": "IPHA", "shortName": "Innate Pharma S.A.", "longName": "Innate Pharma S.A.", "firstTradeDateEpochUtc": 1571319000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "95b2a86c-03b1-3402-a4e5-5bdc8b44e164", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.31, "targetHighPrice": 11.4, "targetLowPrice": 2.73, "targetMeanPrice": 7.4, "targetMedianPrice": 7.94, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 92456000, "totalCashPerShare": 1.143, "ebitda": -7578000, "totalDebt": 39893000, "quickRatio": 3.505, "currentRatio": 3.734, "totalRevenue": 61641000, "debtToEquity": 76.864, "revenuePerShare": 0.766, "returnOnAssets": -0.04039, "returnOnEquity": -0.14276, "freeCashflow": -27067124, "operatingCashflow": -32558000, "revenueGrowth": 0.774, "grossMargins": 0.09116, "ebitdaMargins": -0.12294, "operatingMargins": -0.57221, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]